Five North Sea oil and gas developments sit in the queue behind Rosebank and Jackdaw, according to a Scotsman report on the UK basin's project pipeline.

The arithmetic is simple. Two approvals could unlock five more. The two fields awaiting the regulator's word are among the largest undeveloped prospects left in UK waters, and industry groups have argued for months that each consent decision functions as a signal for the rest of the queue.

What is actually at stake?

Rosebank, operated by Equinor, and Jackdaw, operated by Shell, are the named pair. Both have faced repeated legal and regulatory delay. Their supporters frame them as the last large-scale additions to a basin in managed decline. Opponents frame them as stranded-asset risk dressed as energy security.

The Scotsman's reporting makes the sequencing argument explicit: approve the two headliners, and the five projects behind them move from speculative to bankable. The identity and scale of those five developments was not detailed in the report. That gap matters. A pipeline is only as real as its weakest feasibility study.

Sanctioned versus speculative

This desk keeps the categories separate, and readers should too.

• Sanctioned and proceeding: Neither Rosebank nor Jackdaw belongs here yet. Both await final consent decisions.
• Awaiting approval: Rosebank and Jackdaw, the two largest names in the story.
• Appraisal-stage or queued: The five unnamed follow-on projects. No operator, reserve figure, or startup date accompanied them in the report.

The distinction is the story. Five projects that exist as names in a queue are a different proposition from five projects with field development plans filed.

The basin context, in plain numbers

The UK Continental Sea produces roughly a quarter of the gas it did at its 2000s peak, on North Sea Transition Authority data. Imports fill the difference. Every new field approval therefore carries a framing battle: decline management on one side, transition timing on the other.

The practical effect of approving both fields would be incremental supply late this decade, not transformation. The practical effect of refusing them would be a clearer signal to capital that the queue is closed. That is the trade the regulator weighs.

Why the sequencing claim has traction

Industry's argument runs as follows. Development capital is scarce and mobile. If the largest prospects cannot clear consent, smaller ones will not attract funding at all. Approve the big two, and the risk calculus for the five behind them changes.

Campaigners read the same fact the other way. Approve the big two, they say, and the basin locks in infrastructure that the five then justify retroactively. Both readings are analysis, not fact. We attribute both.

The watch item

The consent decisions themselves. Dates have slipped before, and court challenges remain the standard instrument on both sides of this argument. When the regulator rules on Rosebank and Jackdaw, the five unnamed projects either acquire schedules or remain a list.

The verdict, for now: a queue of five is a claim, not a portfolio.